In the current landscape of the United States market, investors are closely monitoring mixed stock performances as they await key announcements such as the Federal Reserve's interest rate decision and developments in trade negotiations with China. Amid this backdrop, high growth tech stocks continue to capture attention for their potential to thrive despite economic uncertainties, making them a focal point for those seeking opportunities in an evolving market environment.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 20.40% | 34.10% | ★★★★★★ |
| Arcutis Biotherapeutics | 26.42% | 58.25% | ★★★★★★ |
| Ardelyx | 20.63% | 59.87% | ★★★★★★ |
| Travere Therapeutics | 28.83% | 64.80% | ★★★★★★ |
| TG Therapeutics | 25.99% | 38.42% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.67% | 61.11% | ★★★★★★ |
| AVITA Medical | 27.81% | 55.17% | ★★★★★★ |
| Alkami Technology | 22.46% | 76.67% | ★★★★★★ |
| Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
| Lumentum Holdings | 21.34% | 120.49% | ★★★★★★ |
Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
Alvotech (NasdaqGM:ALVO)
Simply Wall St Growth Rating: ★★★★★★
Overview: Alvotech, with a market cap of $2.51 billion, operates through its subsidiaries to develop and manufacture biosimilar medicines for patients globally.
Operations: Biotechnology is the primary revenue segment for Alvotech, generating $491.98 million.
Alvotech's strategic focus on biosimilars is evident with recent FDA approvals, such as SELARSDI and SIMLANDI, enhancing its competitive edge in the high-stakes biotech sector. With a projected annual revenue growth of 30.9% and an anticipated shift to profitability within three years, Alvotech is positioning itself strongly against industry norms. The company's R&D commitment is underscored by significant investments aimed at expanding its biosimilar portfolio, aligning with industry trends towards more cost-effective therapeutic alternatives. This approach not only capitalizes on immediate regulatory milestones but also sets the stage for sustained long-term growth amidst evolving healthcare demands.
- Click to explore a detailed breakdown of our findings in Alvotech's health report.
Explore historical data to track Alvotech's performance over time in our Past section.
Agilysys (NasdaqGS:AGYS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Agilysys, Inc. is a company that develops and markets software-enabled solutions and services for the hospitality industry across North America, Europe, the Asia-Pacific, and India with a market cap of approximately $2.11 billion.
Operations: The company generates revenue primarily from its computer services segment, totaling $263.57 million. With a market capitalization of approximately $2.11 billion, Agilysys focuses on delivering software solutions tailored to the hospitality sector across various regions including North America, Europe, the Asia-Pacific, and India.
Agilysys is making significant strides in the high-growth tech sector, particularly within the hospitality industry. With a robust 17% expected annual revenue growth, Agilysys outpaces the US market average of 8.4%. This growth is complemented by an impressive forecast of 29% earnings growth per year. Recent developments underscore their strategic direction; for instance, Bally's Baton Rouge Hotel has adopted Agilysys solutions for a comprehensive overhaul of its guest and staff experiences, set to launch in fall 2025. These advancements are part of why Agilysys invests heavily in R&D to innovate continuously—ensuring their technology not only meets current demands but sets trends in hospitality management software.
- Dive into the specifics of Agilysys here with our thorough health report.
Assess Agilysys' past performance with our detailed historical performance reports.
Progress Software (NasdaqGS:PRGS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Progress Software Corporation specializes in the development, deployment, and management of AI-powered applications and digital experiences globally, with a market capitalization of approximately $2.61 billion.
Operations: The company generates revenue primarily through its Software & Programming segment, which accounted for $806.74 million.
Progress Software's recent strategic enhancements in AI capabilities, particularly through its Sitefinity and ShareFile platforms, underscore its commitment to integrating advanced technology across business operations. With a 6.2% annual revenue growth and a notable 31.9% expected earnings growth, Progress is leveraging AI to streamline content management and enhance digital security effectively. The company's R&D focus is evident with substantial investments aimed at refining these technologies, ensuring they remain competitive in the fast-evolving tech landscape. This approach not only boosts operational efficiency but also enhances user engagement by simplifying complex processes through AI-driven solutions.
- Click here to discover the nuances of Progress Software with our detailed analytical health report.
Gain insights into Progress Software's past trends and performance with our Past report.
Taking Advantage
- Discover the full array of 231 US High Growth Tech and AI Stocks right here.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Agilysys might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com